Pfizer (PFE) Upgraded at RBC Capital. Here is Why

With an annual dividend yield of 6.57%, Pfizer Inc. (NYSE:PFE) is included among the 12 High Yield Fortune 500 Stocks to Buy Now.

Pfizer (PFE) Upgraded at RBC Capital. Here is Why

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products.

On June 10, Pfizer Inc. (NYSE:PFE) was upgraded by RBC Capital analyst Trung Huynh from ‘Underperform’ to ‘Sector Perform’. Mr. Huynh assigned the stock a price target of $25, indicating a downside of 5% from the current levels.

RBC noted that its overall investment outlook on Pfizer has not substantially changed. However, with the stock down by over 8% from its highs earlier this year and now trading at around 9-times forward earnings, the analyst firm believes that it offers a more balanced risk-reward profile.

RBC also highlighted two key catalysts for Pfizer – Sigvotatug vedotin in second-line lung cancer in mid-2026 and mevro in the latter half of this year. Moreover, the analyst highlighted the pharma company’s strong Q1 fundamentals that should support a potential 2026 guidance upgrade, as well as its robust dividend yield of 6.57%, which may help limit downside risk.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High Yield Crude Oil Stocks to Buy Now and 10 Most Volatile Stocks to Buy in S&P 500

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1